With the label-recommended treatment durations, high SVR12 rates (98.7%, 1,104/1,118) were achieved in all HCV genotypes/subtypes irrespective of the presence of baseline polymorphisms in NS3 and/or NS5A, and baseline resistance testing is not recommended in the current American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) guidelines (40, 41). This evidence concerns the gene KRAS and liver disorder.